Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(50.0%)
Phase 1
2(33.3%)
Phase 2
1(16.7%)
6Total
Phase 4(3)
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05684523Phase 4Completed

Feasibility Study on the Use of Redormin®500 on Day-time Cognition

Role: lead

NCT03482817Phase 1Unknown

Drug Cocktail Interaction Study of St. John's Wort Dry Extract Ze 117

Role: lead

NCT02505191Phase 1Completed

Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117

Role: lead

NCT02189239Phase 4Completed

Efficacy Study of Zeller Entspannung Film Coated Tablets on Acute Stress

Role: lead

NCT00862225Phase 2Completed

MOA Study of Ze 339 in Seasonal Allergic Rhinitis

Role: lead

NCT00878670Phase 4Completed

Investigation of Efficacy and Safety of EPOGAM

Role: lead

All 6 trials loaded